Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-2586-4657
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees70
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions
What is Intec Pharma's stock symbol?
Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."
How were Intec Pharma's earnings last quarter?
Intec Pharma Ltd (NASDAQ:NTEC) released its earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.37) by $0.05. View Intec Pharma's Earnings History.
When is Intec Pharma's next earnings date?
What price target have analysts set for NTEC?
5 Wall Street analysts have issued 12-month price targets for Intec Pharma's stock. Their forecasts range from $8.50 to $16.00. On average, they anticipate Intec Pharma's stock price to reach $13.30 in the next twelve months. This suggests a possible upside of 1,191.3% from the stock's current price. View Analyst Price Targets for Intec Pharma.
What is the consensus analysts' recommendation for Intec Pharma?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intec Pharma.
What are Wall Street analysts saying about Intec Pharma stock?
Here are some recent quotes from research analysts about Intec Pharma stock:
- 1. LADENBURG THALM/SH SH analysts commented, "We are modeling mid-’19 cash is sufficient to fund operations till late 2020. While we appreciate Accordion Pill’s controlled-release abilities and still find AP-CBD/THC’s PK results vs. Sativex as impressive (290-330% and 25-50% higher exposures of CBD and THC, respectively, than Sativex), we have little insight into how the AP-Novartis Phase 1 may come out. Intec’s collaboration on an undisclosed compound was announced. Intec reported it successfully developed an a proprietary Novartis compound that met the prerequisite in vitro specifications. In 1Q’19 a human PK began, with the expectation for completion of the study and the results this summer, with Novartis making a go/no-go decision on a Phase 2 this fall." (8/12/2019)
- 2. Maxim Group analysts commented, "Intec announced the presentation of the results from its PK study on AP-CD/ LD (Accordion Pill – Carbidopa/Levodopa) in Parkinson’s disease (PD) at the XXIV Related Disorders. The data was originally reported on 2/19 (see note, LINK), however, additional detail was provided in the presentation." (6/20/2019)
- 3. According to Zacks Investment Research, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. " (5/7/2019)
Has Intec Pharma been receiving favorable news coverage?
News coverage about NTEC stock has trended negative on Saturday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intec Pharma earned a coverage optimism score of -2.9 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Intec Pharma.
Who are some of Intec Pharma's key competitors?
Some companies that are related to Intec Pharma include Scpharmaceuticals (SCPH), Aptinyx (APTX), Eton Pharmaceuticals (ETON), Avadel Pharmaceuticals (AVDL), Correvio Pharma (CORV), Chembio Diagnostics (CEMI), OASMIA PHARMACE/ADR (OASM), Sesen Bio (SESN), Menlo Therapeutics (MNLO), Fortress Biotech (FBIO), Relmada Therapeutics (RLMD), Galmed Pharmaceuticals (GLMD), Vaccinex (VCNX), Savara (SVRA) and Corvus Pharmaceuticals (CRVS).
What other stocks do shareholders of Intec Pharma own?
Who are Intec Pharma's key executives?
Intec Pharma's management team includes the folowing people:
- Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 52)
- Mr. Nir Sassi, Chief Financial Officer (Age 43)
- Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 50)
- Mr. Walt Addison Linscott, Chief Bus. Officer (Age 58)
- Dr. R. Michael Gendreau, Chief Medical Officer (Age 63)
When did Intec Pharma IPO?
(NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.
Who are Intec Pharma's major shareholders?
Intec Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Migdal Insurance & Financial Holdings Ltd. (2.22%), Harel Insurance Investments & Financial Services Ltd. (1.90%), River & Mercantile Asset Management LLP (0.86%), River & Mercantile Asset Management LLP (0.86%), Renaissance Technologies LLC (0.42%) and Morgan Stanley (0.25%). Company insiders that own Intec Pharma stock include Anthony J Maddaluna and Jeffrey A Meckler. View Institutional Ownership Trends for Intec Pharma.
Which institutional investors are buying Intec Pharma stock?
NTEC stock was purchased by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., River & Mercantile Asset Management LLP, River & Mercantile Asset Management LLP, Migdal Insurance & Financial Holdings Ltd., Renaissance Technologies LLC, JPMorgan Chase & Co. and Morgan Stanley. Company insiders that have bought Intec Pharma stock in the last two years include Anthony J Maddaluna and Jeffrey A Meckler. View Insider Buying and Selling for Intec Pharma.
How do I buy shares of Intec Pharma?
Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Intec Pharma's stock price today?
One share of NTEC stock can currently be purchased for approximately $1.03.
How big of a company is Intec Pharma?
Intec Pharma has a market capitalization of $33.81 million. The biotechnology company earns $-43,540,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Intec Pharma employs 70 workers across the globe.View Additional Information About Intec Pharma.
What is Intec Pharma's official website?
How can I contact Intec Pharma?
Intec Pharma's mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected]
MarketBeat Community Rating for Intec Pharma (NASDAQ NTEC)
MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe NTEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
